Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

Sponsor
Pak Emirates Military Hospital
Study ID
NCT07532876
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Endometriosis (Diagnosis)

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • Elagolix — DRUG
    Elagolix will be administered at 150 mg once daily in this study.
  • Oral Contraceptive (OC) — DRUG
    In this study, administered once daily in a continuous 28-day cycles for 3 months

Study Details

This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.

Key Dates

Start date
May 1, 2026
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Nov 1, 2026

Study Design

Enrollment
90 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Elagolix Group
    45 participants in Elagolix group. Elagolix will be administered at 150 mg once daily in this study.
  • Experimental: OCPs group
    45 Participants in this group. OCPs will be administered once daily in a continuous 28-day cycles for 3 months.

Primary Outcome Measure

Pain Score (Reduction in Pain) [ Time Frame: 24 weeks ]

Related Studies